Form 8-K

8-K — AETHLON MEDICAL INC

Accession: 0001683168-26-004707

Filed: 2026-06-10

Period: 2026-06-10

CIK: 0000882291

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — aethlon_8k.htm (Primary)

EX-99.1 — PRESS RELEASE (aethlon_ex9901.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: aethlon_8k.htm · Sequence: 1

AETHLON MEDICAL, INC. 8-K

false

0000882291

2026-06-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 10, 2026

Aethlon

Medical, Inc.

(Exact name of registrant as specified in its

charter)

Nevada

001-37487

13-3632859

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification No.)

11555

Sorrento Valley Road, Suite

203

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (619) 941-0360

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

AEMD

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

The information provided below in “Item 7.01 - Regulation FD

Disclosure” of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 2.02.

Item

7.01. Regulation FD Disclosure.

On June 10, 2026, Aethlon

Medical, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026.

A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report, including

Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information

in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities

Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly

set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information

in this Current Report that is required to be disclosed solely by Regulation FD

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated June 10, 2026

104

Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 10, 2026

AETHLON MEDICAL, INC.

By:

/s/ James B. Frakes

James B. Frakes

Chief Executive Officer and Chief Financial Officer

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: aethlon_ex9901.htm · Sequence: 2

Exhibit 99.1

Aethlon Medical

Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Australian oncology study advances into Cohort

3 as enrollment continues

Entered

the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained

a focus on managing operating expenses.

Conference Call Today at 4:30 p.m. ET

SAN DIEGO, June 10, 2026 -- Aethlon Medical, Inc.

(the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and

life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31,

2026, and provided an update on recent developments.

Key Highlights

· Advanced the Australian oncology study through

completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating

data to inform future development and dosing strategy.

· Recently treated the first participant in Cohort

3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking

continued enrollment momentum and execution of the study’s final treatment arm.

· Advanced preclinical research evaluating Hemopurifier

applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting

the expansion of the platform’s potential addressable market beyond oncology and infectious disease.

· Continued to strengthen the intellectual property

portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications

for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s

and enhancing long-term platform value.

“Fiscal 2026 was a year of meaningful execution

for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement

into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment

regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual

property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined

with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities

across our clinical and research programs.” said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon

Medical.

Clinical Update

Clinical Progress in Cancer Trial

Enrollment and treatment of participants in Cohort

2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety

concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway

at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week

period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device

deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant

in Cohort 3 maintains the study’s clinical momentum and moves the Company closer to completing enrollment and generating data from all

planned dosing regimens.

Serial Extracellular Vesicle and T cell measurements

on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the

effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial.

This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate

dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents,

Keytruda® or Opdivo®.

Other Recent Developments

During fiscal 2026, we strengthened our intellectual

property portfolio through the issuance of patents in both the United States and Europe covering 2 potential applications of the Hemopurifier

for coronavirus-related conditions; excessive clotting known as coagulopathy during acute COVID-19 infection and symptoms of Long COVID.

These patents extend protection for certain applications of the Hemopurifier into the 2040s.

In addition, we advanced our preclinical extracellular

vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis

and chronic kidney disease. These efforts support the Company’s ongoing evaluation of the Hemopurifier’s potential applications across

multiple disease categories and may create future opportunities to expand the platform into large markets

characterized by significant unmet medical need.

Separately, we continued our evaluation of Hemopurifier

compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer

of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles

by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the

Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully

developed and validated.

Subsequent to fiscal year-end, an interview published

in IEEE Spectrum featuring Aethlon’s Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient

with the Hemopurifier during the 2014 outbreak highlighted the Company’s experience with Ebola treatment efforts. In connection with renewed

public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded

access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global

and U.S. emerging pathogen preparedness efforts, including the World Health Organization’s R&D Blueprint expert panel and the National

Emerging Special Pathogen Training and Education Center.

Financial Results for the Fiscal Year Ended

March 31, 2026

As of March 31, 2026, the Company had approximately

$5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities.

Subsequent to fiscal year-end, the Company strengthened

its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.

Consolidated operating expenses declined 21.9%

year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company’s

clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to

$1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction

in professional fees.

Consistent with the reduction in operating expenses,

the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year.

Other income was approximately $142,000 for the

fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately

$4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges.

Net loss attributable to our common stockholders

was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025.

The consolidated balance sheets for March 31,

2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included

at the end of this release.

Conference Call

Management will host a conference call today,

Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company’s financial results and recent corporate developments. Following

management’s formal remarks, there will be a question-and-answer session.

Interested parties can register for the conference

call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note that registered

participants will receive their dial-in number upon registration.

Interested parties without internet access or

unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical,

Inc. conference call.

A replay of the call will be available approximately

one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical’s website or by dialing

1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number

is 7883435.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational

medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally

with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich

surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies

and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Administration

Breakthrough Device Designation for:

The treatment of individuals with advanced or

metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed

with approved therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage

medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology

and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com

and follow the Company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that

involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,”

“intend,” “plan,” “project,” “will,” “projections,” “estimate,” “potentially”

or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements

regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company’s ability

to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes

or interpretation of such studies; the Company’s ability to manufacture the Hemopurifier in sufficient quantities for clinical and

potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company’s

Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company’s collaborative

research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions; and

the Company’s ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated

with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may

differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon’s

current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such

differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months

without additional financing, the Company’s ability to raise additional capital on terms favorable to the Company, or at all; the Company’s

ability to successfully complete development of the Hemopurifier; the Company’s ability to successfully demonstrate the utility

and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company’s ability to achieve

and realize the anticipated benefits from operational and financial milestones; the Company’s ability to maintain its Nasdaq listing,

the Company’s ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline

expected by the Company; the Company’s ability to enroll additional patients in its oncology clinical trial in Australia, including

on the timeline expected by the Company; the Company’s ability to manage and successfully complete its clinical trials; the Company’s

ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory

requirements; the Company’s collaborative research with UCSF Long Covid Clinic; and the Company’s ability to further research

potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and

uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated

in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for

the year ended March 31, 2026, and in the Company’s other filings with the Securities and Exchange Commission, including its Quarterly

Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made.

Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future

events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established,

and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility

study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.

Company Contact:

Jim Frakes

Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

AETHLON MEDICAL, INC. AND SUBSIDIARY

Consolidated Balance Sheets

Unaudited

ASSETS

March 31, 2026

March 31, 2025

CURRENT ASSETS

Cash and cash equivalents

$ 5,026,458

$ 5,501,261

Deferred offering costs

210,985

–

Prepaid expenses and other current assets

332,094

448,539

TOTAL CURRENT ASSETS

5,569,537

5,949,800

Property and equipment, net

356,822

676,220

Operating lease right-of-use asset, net

307,820

601,846

Patents, net

–

550

Restricted cash

98,928

97,813

Deposits

–

33,305

TOTAL ASSETS

$ 6,333,107

$ 7,359,534

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable

$ 384,550

$ 534,524

Due to related parties

68,250

579,565

Operating lease liability, current portion

336,718

313,033

Other current liabilities

657,317

472,164

TOTAL CURRENT LIABILITIES

1,446,835

1,899,286

Operating lease liability, less current portion

–

336,718

TOTAL LIABILITIES

1,446,835

2,236,004

STOCKHOLDERS' EQUITY

Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2026 and 6,000,000 authorized at March 31, 2025; 1,570,449 shares issued and outstanding at March 31, 2026 and 258,531 shares issued and 201,074 outstanding at March 31, 2025

1,570

259

Additional paid-in capital

180,023,691

173,095,221

Accumulated other comprehensive loss

(32,703 )

(17,133 )

Accumulated deficit

(175,106,286 )

(167,954,817 )

TOTAL STOCKHOLDERS' EQUITY

4,886,272

5,123,530

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$ 6,333,107

$ 7,359,534

AETHLON MEDICAL, INC. AND SUBSIDIARY

Consolidated Statements of Operations and Comprehensive Loss

For the fiscal years ended March 31, 2026 and 2025

Unaudited

Fiscal Year

Ended 3/31/26

Ended 3/31/25

OPERATING EXPENSES

Professional fees

$ 1,809,181

$ 2,224,092

Payroll and related expenses

2,788,005

3,874,092

General and administrative

2,696,445

3,243,181

Total operating expenses

7,293,631

9,341,365

OPERATING LOSS

(7,293,631 )

(9,341,365 )

OTHER INCOME (EXPENSE), NET

Interest income

156,534

298,122

Other income

–

324,450

Interest expense

(14,372 )

(10,109 )

Other expense

–

(4,659,188 )

Total other income (expense), net

142,162

(4,046,725 )

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

(7,151,469 )

(13,388,090 )

Basic and diluted net loss per share attributable to common stockholders

$ (10.61 )

$ (85.77 )

Weighted average number of common shares outstanding - basic and diluted

673,945

156,085

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

(7,151,469 )

(13,388,090 )

OTHER COMPREHENSIVE LOSS

(15,570 )

(10,193 )

COMPREHENSIVE LOSS

$ (7,167,039 )

$ (13,398,283 )

GRAPHIC

Filename: image_001.jpg · Sequence: 6

Binary file (16545 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 10, 2026

Entity File Number

001-37487

Entity Registrant Name

Aethlon

Medical, Inc.

Entity Central Index Key

0000882291

Entity Tax Identification Number

13-3632859

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11555

Sorrento Valley Road

Entity Address, Address Line Two

Suite

203

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92121

City Area Code

619

Local Phone Number

941-0360

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value per share

Trading Symbol

AEMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration